Please select the option that best describes you:
Would you offer OFS 5 years out from diagnosis in a young patient whose menses have returned with previously treated IDC?
Would you consider OFS this far out from diagnosis and treatment in a young patient with high grade IDC was treated during pregnancy with neoadjuvant AC + T with extensive response but final path with probable tumor footprint in 1 to 2 lymph nodes? She was treated 5 years ago and her menses have returned.
Answer from: Medical Oncologist at Academic Institution
I would if you are considering extending her endocrine therapy based on clinical risk or other info like BCI testing. If she took tamoxifen alone then I would discuss OFS+AI based on the benefit seen in MA.17 for letrozole x 5 years after tam x 5 years. Shouldn't matter if the menopause is natural o...
Sign in or Register to read more